Show results for
Refine by
Non Small Cell Lung Cancer Equipment Supplied In Europe
17 equipment items found
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation. Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical ...
Manufactured by:Virasoft Inc. based inSarıyer, TURKEY
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, B cells, macrophages, dendritic cells, mast ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB is designed to elicit an anti-tumor immune response by simultaneous ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Avastin is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). With the initial approval in the United States for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target protein are replaced with epitopes from a cancer ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and poor patient prognosis. Inhibition of XPO1 has been shown to restore tumor suppressor function and proper cell cycle regulation, leading to apoptosis of ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
Manufactured by:INTERmedic Arfran based inBarcelona, SPAIN
INTERmedic, worldwide leader in photodynamic therapy for pulmonology (lung cancer), gastroenterology (Barrett’s esophagus, esophageal cancer), urology (prostate cancer) among others, presents Multidiode™ PDT, an innovative technology to treat dermatological pathologies such as basal cell carcinoma, cholangiocarcinoma or hidradenitis ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
ENKASTIM-ev is an innovative product candidate representing a new class of therapy known as Active Cellular Immunotherapies (ACIs). ACI is a treatment approach which capitalizes on the power of vital human cells to re-engage the patient's own immune system to fight cancer. The product induces a targeted immune response against surface-bound heat shock protein 70 (Hsp70). Surface-bound Hsp70 is a ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
by:Pure Biologics SA based inWroclaw, POLAND
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project embraces a novel approach, aiming to develop a drug based on a bimodal fusion protein, which synergistically activates NK cells and minimizes ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
Innovation is at the heart of everything we do. Our proprietary drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your ...